Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, 2-arm open-label, randomized comparative phase II study. The objective
of this trial is to prospectively evaluate whether a sequential approach with an induction
period of 12 weeks with encorafenib + binimetinib followed by combination immunotherapy with
nivolumab + ipilimumab improves progression free survival compared to combination
immunotherapy nivolumab + ipilimumab alone in patients with BRAF V600 mutation-positive
unresectable or metastatic melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC